Insider Selling: Bioventus Inc. (NYSE:BVS) CFO Sells 6,498 Shares of Stock

Bioventus Inc. (NYSE:BVS - Get Free Report) CFO Mark Leonard Singleton sold 6,498 shares of the stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $10.19, for a total value of $66,214.62. Following the transaction, the chief financial officer now owns 118,817 shares of the company's stock, valued at approximately $1,210,745.23. This trade represents a 5.19 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Mark Leonard Singleton also recently made the following trade(s):

• On Monday, December 23rd, Mark Leonard Singleton sold 10,733 shares of Bioventus stock. The stock was sold at an average price of $10.53, for a total transaction of $113,018.49.

Bioventus Stock Performance

NYSE:BVS traded up $0.06 during mid-day trading on Friday, hitting $10.01. The stock had a trading volume of 427,919 shares, compared to its average volume of 219,538. Bioventus Inc. has a twelve month low of $3.90 and a twelve month high of $14.38. The stock has a market cap of $812.31 million, a price-to-earnings ratio of -16.41 and a beta of 0.85. The company's 50 day simple moving average is $10.32 and its 200 day simple moving average is $10.85. The company has a debt-to-equity ratio of 1.85, a quick ratio of 0.99 and a current ratio of 1.41.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on BVS shares. Canaccord Genuity Group increased their price objective on shares of Bioventus from $12.00 to $15.00 and gave the stock a "buy" rating in a research note on Wednesday, November 6th. JPMorgan Chase & Co. upgraded shares of Bioventus from an "underweight" rating to a "neutral" rating and increased their price objective for the stock from $12.00 to $13.00 in a research note on Tuesday, December 17th.

Institutional Investors Weigh In On Bioventus

Hedge funds have recently bought and sold shares of the company. Royce & Associates LP bought a new position in Bioventus in the 3rd quarter valued at about $8,337,000. Vanguard Group Inc. raised its holdings in Bioventus by 18.7% in the 4th quarter. Vanguard Group Inc. now owns 2,462,081 shares of the company's stock valued at $25,852,000 after acquiring an additional 388,174 shares during the period. Segall Bryant & Hamill LLC bought a new position in Bioventus in the 3rd quarter valued at about $4,515,000. Driehaus Capital Management LLC raised its holdings in Bioventus by 33.7% in the 4th quarter. Driehaus Capital Management LLC now owns 1,119,855 shares of the company's stock valued at $11,758,000 after acquiring an additional 282,341 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new position in Bioventus in the 3rd quarter valued at about $3,092,000. 62.94% of the stock is currently owned by institutional investors and hedge funds.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.